Crossmark

Antikörper zur INS-Therapie beweist sich in Phase-III-Studie

Crossref DOI link: https://doi.org/10.1007/s15014-025-5826-9

Published Online: 2025-12-10

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Facharztmagazine, Redaktion
License Information

Text and Data Mining valid from 2025-12-01

Version of Record valid from 2025-12-01
More Information

Article History

First Online: 10 December 2025

Free to read: This content has been made available to all.